ArticleScientific reports2025
Disproportionality analysis of drug-induced erectile dysfunction using FAERS database.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database.Drug safety · 2026Article
- Dysregulated fibroblast-immune crosstalk drives statin-associated erectile dysfunction: integrative evidence from pharmacovigilance and single-cell transcriptomics.Frontiers in pharmacology · 2026Article
- Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study.Clinical epidemiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study employs a comprehensive approach to systematically identify drugs associated with Drug-Induced Erectile Dysfunction (DIED) risk and constructs a DIED risk assessment platform. Utilizing the FAERS database, we identified "Erectile Dysfunction," "Organic Erectile Dysfunction," and "Psychogenic Erectile Dysfunction" as relevant Preferred Terms (PTs) for DIED. After excluding patients diagnosed with Erectile Dysfunction (ED), drugs suspected as primary suspects (PS) in ≥ 10 DIP events were selected as target drugs. Through disproportionality analysis, we identified positive signals for these drugs using ROR, PRR, BCPNN, and EBGM. We further assessed the independent effects of positive drugs by adjusting for confounding factors such as age using multivariate logistic regression. Subsequently, we obtained the median onset time and outcome events of DIED for target drugs and compared them by age. The DIED platform is accessible for free at http://116.196.73.86:3838/ADR-DATABASE/DIED/. A total of 67 target drugs were identified as PS in DIED events with 10 or more cases. Based on disproportionality analysis, we further identified 28 drugs with DIED risk signals. Multivariate logistic regression revealed that 23 of these drugs were independent risk factors for DIED (OR > 1 and P < 0.05). Analysis of outcome events showed a significant difference in the median onset time of DIED between different age groups. This study identified 28 drugs associated with DIED risk. We also found some previously unreported DIP risk drugs, including omeprazole, antihypertensive drugs, etc., which should be of clinical concern.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.